Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Oncology Institute (TOI) EBITDA Margin (2021 - 2025)

Oncology Institute (TOI) has disclosed EBITDA Margin for 5 consecutive years, with 5.16% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA Margin rose 790.0% year-over-year to 5.16%, compared with a TTM value of 8.05% through Sep 2025, up 789.0%, and an annual FY2024 reading of 14.47%, up 840.0% over the prior year.
  • EBITDA Margin was 5.16% for Q3 2025 at Oncology Institute, up from 8.5% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 1.89% in Q2 2021 and bottomed at 77.56% in Q4 2021.
  • Average EBITDA Margin over 5 years is 20.31%, with a median of 15.86% recorded in 2023.
  • Peak annual rise in EBITDA Margin hit 4310bps in 2022, while the deepest fall reached -2965bps in 2022.
  • Year by year, EBITDA Margin stood at 77.56% in 2021, then skyrocketed by 56bps to 34.47% in 2022, then soared by 51bps to 16.88% in 2023, then surged by 35bps to 10.97% in 2024, then soared by 53bps to 5.16% in 2025.
  • Business Quant data shows EBITDA Margin for TOI at 5.16% in Q3 2025, 8.5% in Q2 2025, and 8.52% in Q1 2025.